CQS (US)’s BioMarin Pharmaceuticals BMRN Stock Holding History

CQS (US)’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-40,129	Closed	-$3.39M	–	115
2020 Q1	$3.39M	Sell	40,129 -19,493	-33%	-$1.68M	0.25%	75
2019 Q4	$5.04M	Buy	+59,622	New	+$4.5M	0.24%	91

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

CQS (US)'s BMRN Position: Q2 2020 in Review

CQS (US) sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2020, closing a stake of 40,129 shares — an estimated $3.39M sold.

CQS (US) first reported a position in BMRN in Q4 2019 and held it in 2 quarters. The position peaked at $5.04M in Q4 2019. 527 funds tracked by Wall St. Rank hold BMRN as of Q2 2020.

CQS (US) reported no remaining BioMarin Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
CQS (US) sold 40,129 BioMarin Pharmaceuticals shares in Q2 2020, an estimated $3.39M.
CQS (US) first reported a position in BioMarin Pharmaceuticals in Q4 2019 and held it in 2 quarters.
CQS (US)'s BioMarin Pharmaceuticals position peaked at $5.04M in Q4 2019.
527 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2020.

Based on CQS (US)'s 13F filing for Q2 2020, filed 7 Aug 2020.